NASDAQ: URGNUrogen Pharma Ltd Stock
$28.18+0.93 (+3.41%)
Updated Jun 9, 2026
URGN Price
$28.18
Fair Value Price
N/A
Market Cap
$1.37B
52 Week Low
$6.92
52 Week High
$32.37
P/E
-10.28x
P/B
-11.05x
P/S
6.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$140.49M
Earnings
-$133.23M
Gross Margin
89.9%
Operating Margin
-87.44%
Profit Margin
-94.8%
Debt to Equity
-3.04
Operating Cash Flow
-$166M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
URGN Overview
UroGen Pharma Ltd. is a biotechnology firm dedicated to creating and marketing innovative treatments for specialized cancers and diseases affecting the urinary tract. Its proprietary technology includes RTGel, a biocompatible polymer with reverse thermal gelation properties designed to enhance the efficacy of existing medications. The company also markets Jelmyto, used in pyelocalyceal solutions. A key component of its pipeline is UGN-102, currently undergoing Phase III clinical trials. This investigational drug targets various forms of non-muscle invasive urothelial cancer, specifically low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Additionally, UroGen is developing UGN-301 for high-grade non-muscle invasive bladder cancer. The company holds a licensing agreement with Allergan Pharmaceuticals International Limited, enabling the development and commercialization of pharmaceutical products incorporating both RTGel and clostridial toxins. It also partners with Agenus Inc. to advance, produce, and commercialize Agenus's products for intravesical delivery in urinary tract cancer treatment. Furthermore, a strategic research collaboration with MD Anderson aims to progress experimental treatments for high-grade bladder cancer. Established in 2004, UroGen Pharma Ltd. operates out of Princeton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine URGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
URGN
Ranked#71 of 460
Ranked#71 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.19 | A | |
| $52.99 | A | |
| $15.78 | A |
Be the first to know about important URGN news, forecast changes, insider trades & much more!
URGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how URGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
URGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
URGN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
URGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more URGN due diligence checks available for Premium users.
Valuation
URGN fair value
Fair Value of URGN stock based on Discounted Cash Flow (DCF)
Price
$28.18
Fair Value
-$31.43
Undervalued by
189.66%
URGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
URGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.28x
Industry
17.38x
Market
14.33x
URGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-11.05x
Industry
4.77x
URGN's financial health
Profit margin
Revenue
$51.0M
Net Income
-$23.6M
Profit Margin
-46.3%
URGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
URGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$253.7M
Liabilities
$377.9M
Debt to equity
-3.04
URGN's short-term assets ($237.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
URGN's long-term liabilities ($327.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
URGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
URGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$45.3M
Investing
-$20.7M
Financing
$65.2M
URGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
URGN vs Biotech Stocks
Urogen Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.